Ryan Edward Brown's Insider Trades & SAST Disclosures
Ryan Edward Brown's most recent trade in Sarepta Therapeutics Inc was a trade of 23,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 21, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ryan Edward Brown.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 23,500 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.77 per share. | 21 Jun 2024 | 23,500 | 56,086 (0%) | 0% | 62.8 | 1,475,095 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 162.65 per share. | 21 Jun 2024 | 17,581 | 23,518 (0%) | 0% | 162.7 | 2,859,550 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 158.07 per share. | 21 Jun 2024 | 7,644 | 48,442 (0%) | 0% | 158.1 | 1,208,287 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 34,938 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 0 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 6,250 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 5,500 | 5,500 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 161.82 per share. | 21 Jun 2024 | 4,168 | 41,099 (0%) | 0% | 161.8 | 674,466 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 163.53 per share. | 21 Jun 2024 | 3,840 | 19,678 (0%) | 0% | 163.5 | 627,955 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 164.52 per share. | 21 Jun 2024 | 2,549 | 17,129 (0%) | 0% | 164.5 | 419,361 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 164.64 per share. | 21 Jun 2024 | 2,352 | 32,586 (0%) | 0% | 164.6 | 387,233 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 159.14 per share. | 21 Jun 2024 | 2,200 | 46,242 (0%) | 0% | 159.1 | 350,108 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 160.31 per share. | 21 Jun 2024 | 975 | 45,267 (0%) | 0% | 160.3 | 156,302 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.14 per share. | 07 Mar 2024 | 899 | 28,688 (0%) | 0% | 123.1 | 110,703 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.49 per share. | 07 Mar 2024 | 506 | 29,587 (0%) | 0% | 120.5 | 60,968 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.32 per share. | 04 Mar 2024 | 1,734 | 30,093 (0%) | 0% | 125.3 | 217,305 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 6,000 | 33,827 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 125.34 per share. | 01 Mar 2024 | 2,000 | 31,827 (0%) | 0% | 125.3 | 250,680 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.19 per share. | 01 Mar 2024 | 269 | 27,827 (0%) | 0% | 126.2 | 33,945 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.60 per share. | 01 Jun 2023 | 89 | 28,096 (0%) | 0% | 123.6 | 11,000 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.19 per share. | 08 Mar 2023 | 635 | 28,185 (0%) | 0% | 153.2 | 97,276 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 4,500 | 28,820 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.21 per share. | 06 Mar 2023 | 1,154 | 24,491 (0%) | 0% | 157.2 | 181,420 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.21 per share. | 06 Mar 2023 | 171 | 24,320 (0%) | 0% | 157.2 | 26,883 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.57 per share. | 01 Mar 2023 | 196 | 25,645 (0%) | 0% | 147.6 | 28,924 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 48,000 | 48,000 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 8,000 | 25,895 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.20 per share. | 04 Mar 2022 | 1,136 | 18,048 (0%) | 0% | 79.2 | 89,971 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.36 per share. | 04 Mar 2022 | 153 | 17,895 (0%) | 0% | 79.4 | 12,142 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.05 per share. | 01 Mar 2022 | 184 | 19,184 (0%) | 0% | 75.0 | 13,809 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.02 per share. | 01 Jun 2021 | 64 | 19,368 (0%) | 0% | 76.0 | 4,865 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2021 | 15,000 | 19,622 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.97 per share. | 28 Feb 2021 | 216 | 4,622 (0%) | 0% | 87.0 | 18,786 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Edward Brown | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.76 per share. | 28 Feb 2021 | 190 | 19,432 (0%) | 0% | 80.8 | 15,344 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges